NCT05637541View on ClinicalTrials.gov

Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

July 24, 2024

Study Completion Date

August 24, 2024

Conditions
Chronic Hepatitis b
Interventions
DRUG

GST-HG141

The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment

Trial Locations (1)

130021

The first hospital of Jilin University, Changchun

All Listed Sponsors
lead

Fujian Akeylink Biotechnology Co., Ltd.

INDUSTRY